While no significant differences were observed in individual biomarker levels between the two groups, the identified correlations suggest that specific biomarkers, such as SEMA3A and neurofilaments, may be associated with neurodegeneration in the progressive phase of MS. Here, SEMA3A is linked to myeloid sarcoma.